Organon Co Stock Performance
| OGN Stock | USD 14.89 0.16 1.09% |
The company holds a Beta of 0.37, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Organon's returns are expected to increase less than the market. However, during the bear market, the loss of holding Organon is expected to be smaller as well. At this point, Organon has a negative expected return of -0.64%. Please make sure to check Organon's value at risk, as well as the relationship between the daily balance of power and price action indicator , to decide if Organon performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Organon Co has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of sluggish performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 2.35 | Five Day Return (0.07) | Year To Date Return 3.6 | Ten Year Return (54.17) | All Time Return (54.17) |
Forward Dividend Yield 0.0752 | Payout Ratio 0.2738 | Forward Dividend Rate 1.12 | Dividend Date 2024-12-12 | Ex Dividend Date 2024-11-12 |
1 | Disposition of 1145 shares by Susanne Fiedler of Organon at 20.35 subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of 28996 shares by Daniel Karp of Organon at 36.11 subject to Rule 16b-3 | 09/09/2024 |
| Organon dividend paid on 12th of September 2024 | 09/12/2024 |
3 | Disposition of tradable shares by Daniel Karp of Organon subject to Rule 16b-3 | 09/17/2024 |
4 | Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 | 09/20/2024 |
5 | Ahead of Organon Q3 Earnings Get Ready With Wall Street Estimates for Key Metrics | 10/28/2024 |
6 | US-amerikanische FDA akzeptiert BLA fr HLX14 den Biosimilar-Kandidat zu PROLIAXGEVA | 10/31/2024 |
7 | Organon Third Quarter 2024 Earnings EPS US1.39 | 11/01/2024 |
8 | Disposition of 2300 shares by Arjona Ferreira Juan Camilo of Organon at 15.8 subject to Rule 16b-3 | 11/07/2024 |
9 | Acquisition by Ezekowitz Alan of 9638 shares of Organon subject to Rule 16b-3 | 11/08/2024 |
10 | Organon Co. Announces 0.28 Quarterly Dividend | 11/11/2024 |
11 | Los Angeles Capital Management LLC Grows Stock Holdings in Organon Co. | 11/12/2024 |
| Begin Period Cash Flow | 706 M |
Organon |
Organon Relative Risk vs. Return Landscape
If you would invest 2,263 in Organon Co on August 24, 2024 and sell it today you would lose (774.00) from holding Organon Co or give up 34.2% of portfolio value over 90 days. Organon Co is generating negative expected returns assuming volatility of 1.8245% on return distribution over 90 days investment horizon. In other words, 16% of stocks are less volatile than Organon, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Organon Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Organon's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Organon Co, and traders can use it to determine the average amount a Organon's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.3482
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | OGN |
Estimated Market Risk
| 1.82 actual daily | 16 84% of assets are more volatile |
Expected Return
| -0.64 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.35 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Organon is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Organon by adding Organon to a well-diversified portfolio.
Organon Fundamentals Growth
Organon Stock prices reflect investors' perceptions of the future prospects and financial health of Organon, and Organon fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Organon Stock performance.
| Return On Asset | 0.0791 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 11.82 B | ||||
| Shares Outstanding | 257.54 M | ||||
| Price To Earning | 4.20 X | ||||
| Price To Book | 7.78 X | ||||
| Price To Sales | 0.60 X | ||||
| Revenue | 6.26 B | ||||
| Gross Profit | 3.89 B | ||||
| EBITDA | 1.44 B | ||||
| Net Income | 1.02 B | ||||
| Cash And Equivalents | 706 M | ||||
| Cash Per Share | 2.14 X | ||||
| Total Debt | 8.76 B | ||||
| Current Ratio | 1.58 X | ||||
| Book Value Per Share | 1.91 X | ||||
| Cash Flow From Operations | 799 M | ||||
| Earnings Per Share | 5.05 X | ||||
| Market Capitalization | 3.83 B | ||||
| Total Asset | 12.06 B | ||||
| Retained Earnings | 443 M | ||||
| Working Capital | 1.59 B | ||||
About Organon Performance
By examining Organon's fundamental ratios, stakeholders can obtain critical insights into Organon's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Organon is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 190.84 | 111.92 | |
| Return On Tangible Assets | 0.15 | 0.14 | |
| Return On Capital Employed | 0.15 | 0.29 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | (14.61) | (13.88) |
Things to note about Organon performance evaluation
Checking the ongoing alerts about Organon for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Organon help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Organon generated a negative expected return over the last 90 days | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Disposition of 42553 shares by Daniel Karp of Organon subject to Rule 16b-3 |
- Analyzing Organon's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Organon's stock is overvalued or undervalued compared to its peers.
- Examining Organon's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Organon's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Organon's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Organon's stock. These opinions can provide insight into Organon's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.081 | Dividend Share 1.12 | Earnings Share 5.05 | Revenue Per Share 24.984 | Quarterly Revenue Growth 0.041 |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.